Lufax Holding Ltd vs Koninklijke Philips NV — how do they compare? Lufax Holding Ltd trades at $0.99 (market cap $982.89M), while Koninklijke Philips NV trades at $24.24 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 23.9× Lufax Holding Ltd's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Koninklijke Philips NV for 84 Days on average.
| LU | PHG | |
|---|---|---|
Market Cap | $982.89M | $23.52B |
Volume | 3,323,384 | 1,635,069 |
Sector | Financials | Health |
52-Week High | $3.93 | $32.91 |
52-Week Low | $0.95 | $23.81 |
Typical Hold Time | 13 Days | 84 Days |
Enterprise Value | $58.81B | $29.87B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
Lufax (LU) trades at $0.986, up 0.47% on the day, but shows significant fundamental challenges with consecutive quarterly losses and declining revenue. The company recently completed a 10:1 reverse stock split and faces bearish technical signals despite some oversold RSI readings. Analyst sentiment remains predominantly bullish with 69% buy ratings, pointing to potential value in the depressed valuation multiples.
The investment case hinges on Lufax's deep value proposition trading at 0.07x book value, but requires successful navigation of regulatory headwinds and return to profitability. Key risks include persistent net losses, Chinese regulatory uncertainty, and declining top-line performance that could pressure the stock further despite strong institutional backing from parent company Ping An.
PHG trades at $24.225, up 0.56% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent news highlights Philips' innovation in healthcare technology including new product launches and strategic partnerships.
While valuation appears reasonable with P/E of 18.94 and EV/EBITDA of 8.86, the stock faces headwinds from bearish technical indicators and mixed analyst sentiment. Investment opportunity lies in continued earnings momentum and healthcare technology leadership, balanced against competitive pressures and execution risks in a challenging market environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →